England to Review Rejection of Alzheimer’s Drugs for NHS

England’s drug price regulator will reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s disease treatment — and another made Eisai Co. and Biogen Inc. — in the state-run National Health Service, following successful appeals by the companies.

The National Institute for Health and Care Excellence will now re-look at its initial guidance that found the benefits of the two drugs, Lilly’s donanemab and lecanemab made by Eisai and Biogen, were not sufficient to justify the price for the public health service.